- T1- oder T2-Tumoren < 40mm
- Tiefeninvasion > 1 mm.
- Klinisch unauffällige Leistenlymphknoten, cNo
- 37,5% lateralisierter Tumor
- 62,5% Mittellinientumor
- 93,5% unifokaler Tumor
- Radikale lokale Exzision (88,8%)
- Sentinel-Node-Prozedur
- 26,2% LK-Metastasen: inguino-femorale Lymphonodektomie
- 276 negativer Sentinell: Überwachungsstudie.
| Nebenwirkungen | Sentinel-OP | ingino-femorale Lymphonodektomie | Lymphödem | 1,9% | 25,2% |
| Wundheilungsstörung | 11,7% | 34% |
| wiederholtes Erysipel | 0,4% | 16,2% |
- Follow-up: 35M
- inguinales Rezidiv: 8 von 276
- Rezidivtherapie:
- inguino-femorale Lymphonodektomie
- Radiochemotherapie
- lokale Kontrolle: 4 von 8
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.
JCO 26(2008):884-889
2.) Achimas-Cadariu P, et al.:
Assessment of the sentinel lymph node in patients with invasive squamous carcinoma of the vulva.
Acta Obstet Gyn Scan 88(2009):1209-1210
3.) Hampl M, et al.:
Validation of the accuracy of the sentinel lymph node procedure in patients with vulva cancer: Results of a multicenter study in Germany.
Gynecol Oncol 111(2008):282-288
